行情

SCYX

SCYX

SCYNEXIS
NASDAQ

实时行情|Nasdaq Last Sale

0.7700
+0.0101
+1.33%
已收盘, 17:56 04/02 EDT
开盘
0.8000
昨收
0.7599
最高
0.8025
最低
0.7635
成交量
31.99万
成交额
--
52周最高
1.900
52周最低
0.5000
市值
7,501.13万
市盈率(TTM)
-0.7825
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SCYX价格均价为5.07,最高价位10.00,最低价为3.500。

EPS

SCYX 新闻

更多
  • “50美分”交易员狂赚4亿美元后,将目标转向黄金
  • 新浪财经综合 · 1小时前
  • 当两个明斯基过程遭遇大幅冲击:美国企业面临大考
  • 新浪财经-自媒体综合 · 1小时前
  • 华尔街给美财政部“上课”:宽信用得看银行脸色
  • 界面新闻 · 1小时前
  • 瑞幸“造假门”后:中介机构或连坐 被监管纳入核查
  • 新浪财经 · 1小时前

所属板块

制药
+2.64%
制药与医学研究
+2.79%

热门股票

代码
价格
涨跌幅

SCYX 简况

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
展开

微牛提供SCYNEXIS Inc(NASDAQ-SCYX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SCYX股票新闻,以帮助您做出投资决策。